New drug trial offers hope for tough blood cancers
NCT ID NCT00726232
Summary
This study tested whether the drug ruxolitinib could help control two rare blood disorders where standard treatment had failed. It involved 73 adults with either polycythemia vera or essential thrombocythemia who no longer responded to their usual medication. Researchers tested different dosing schedules to find the best balance between effectiveness and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM (MPN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Houston, Texas, 77030, United States
-
Study site
Bergamo, Italy
-
Study site
Florence, Italy
-
Study site
Pavia, Italy
Conditions
Explore the condition pages connected to this study.